eprintid: 10051244
rev_number: 18
eprint_status: archive
userid: 608
dir: disk0/10/05/12/44
datestamp: 2018-07-02 10:34:42
lastmod: 2021-10-10 22:31:17
status_changed: 2018-07-02 10:34:42
type: article
metadata_visibility: show
creators_name: Blennow, K
creators_name: Zetterberg, H
title: The Past and the Future of Alzheimer's Disease Fluid Biomarkers
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Alzheimer’s disease, amyloid, biomarkers, cerebrospinal fluid, neurogranin, plasma, tau
note: Copyright © 2018 IOS Press and the authors. This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/).
abstract: Following the development of the first methods to measure the core Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers total-tau (T-tau), phosphorylated tau (P-tau) and the 42 amino acid form of amyloid-β (Aβ42), there has been an enormous expansion of this scientific research area. Today, it is generally acknowledged that these biochemical tests reflect several central pathophysiological features of AD and contribute diagnostically relevant information, also for prodromal AD. In this article in the 20th anniversary issue of the Journal of Alzheimer’s Disease, we review the AD biomarkers, from early assay development to their entrance into diagnostic criteria. We also summarize the long journey of standardization and the development of assays on fully automated instruments, where we now have high precision and stable assays that will serve as the basis for common cut-off levels and a more general introduction of these diagnostic tests in clinical routine practice. We also discuss the latest expansion of the AD CSF biomarker toolbox that now also contains synaptic proteins such as neurogranin, which seemingly is specific for AD and predicts rate of future cognitive deterioration. Last, we are at the brink of having blood biomarkers that may be implemented as screening tools in the early clinical management of patients with cognitive problems and suspected AD. Whether this will become true, and whether it will be plasma Aβ42, the Aβ42/40 ratio, or neurofilament light, or a combination of these, remains to be established in future clinical neurochemical studies.

This paper in the 20th anniversary issue of the Journal of Alzheimer’s Disease is a review on the development of cerebrospinal fluid (CSF) biomarkers, from early assay development to the current status with fully automated assays and the highest level of standardization, with focus on the most important, but also most troublesome, Alzheimer’s disease (AD) biomarker; Aβ42. We also review the path from early clinical biomarker studies to the very extensive and consistent clinical validation of the diagnostic performance of the core AD CSF biomarkers we have today. Last, we give an update on recent developments, including biomarkers for synaptic proteins in CSF and the promise of blood biomarkers with potential application as screening tools.
date: 2018
date_type: published
publisher: IOS PRESS
official_url: http://dx.doi.org/10.3233/JAD-170773
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
article_type_text: Review
verified: verified_manual
elements_id: 1544611
doi: 10.3233/JAD-170773
lyricists_name: Zetterberg, Henrik
lyricists_id: HZETT94
actors_name: Bracey, Alan
actors_id: ABBRA90
actors_role: owner
full_text_status: public
publication: Journal of Alzheimer's Disease
volume: 62
number: 3
pagerange: 1125-1140
pages: 16
issn: 1875-8908
citation:        Blennow, K;    Zetterberg, H;      (2018)    The Past and the Future of Alzheimer's Disease Fluid Biomarkers.                   Journal of Alzheimer's Disease , 62  (3)   pp. 1125-1140.    10.3233/JAD-170773 <https://doi.org/10.3233/JAD-170773>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10051244/1/jad%252F2018%252F62-3%252Fjad-62-3-jad170773%252Fjad-62-jad170773.pdf